Posted by Michael Wonder on 23 Apr 2024
Abeona Therapeutics provides regulatory update on Pz-cel
22 April 2024 - Abeona Therapeutics today announced a regulatory update for prademagene zamikeracel (pz-cel).
The US FDA has issued a complete response letter in response to the Company’s biologics license application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.
